GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (NAS:KPRX) » Definitions » Debt-to-Equity

Kiora Pharmaceuticals (Kiora Pharmaceuticals) Debt-to-Equity : 0.02 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Kiora Pharmaceuticals Debt-to-Equity?

Kiora Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.05 Mil. Kiora Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.06 Mil. Kiora Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $6.11 Mil. Kiora Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kiora Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

KPRX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.09   Med: 0.01   Max: 0.06
Current: 0.02

During the past 12 years, the highest Debt-to-Equity Ratio of Kiora Pharmaceuticals was 0.06. The lowest was -0.09. And the median was 0.01.

KPRX's Debt-to-Equity is ranked better than
87.76% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs KPRX: 0.02

Kiora Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Kiora Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals Debt-to-Equity Chart

Kiora Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.06 0.01 0.01 0.02

Kiora Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 - - 0.02

Competitive Comparison of Kiora Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Kiora Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiora Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Debt-to-Equity falls into.



Kiora Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kiora Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Kiora Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kiora Pharmaceuticals  (NAS:KPRX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Kiora Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiora Pharmaceuticals (Kiora Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
332 Encinitas Blvd, Suite 102, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in one reportable segment operations and manages.
Executives
Carmine N. Stengone director 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Melissa Tosca officer: EVP of Finance C/O KIORA PHARMACEUTICALS, INC., 1371 EAST 2100 SOUTH, SUITE 200, SALT LAKE CITY UT 84105
Susan L. Drexler officer: Interim CFO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Erin Parsons director 97 WILLISTON RD, BROOKLINE MA 02445
David Hollander director C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Brian M. Strem director, officer: President and CEO C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Eric Joseph Daniels officer: Chief Development Officer C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Armistice Capital Master Fund Ltd. director, 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Aron Shapiro director C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Kenneth L Gayron director 75 NETWORK DRIVE, BURLINGTON MA 34212
Franz Obermayr officer: Acting CEO C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM MA 02452
Bernard Malfroy-camine director C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110
Thomas Hancock director C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110